Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 15/20 | 0.48 |
| ▸ | AGXT | P21549 | 11/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA5A | P35218 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.44 |
| ▸ | CYP51A1 | Q16850 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18074915 | 0.83 | CYP51A1 (0.45) | CA1CA2CA5ACA9CA5B | |
| SCHEMBL22683759 | 0.80 | CYP51A1 (0.42) | CA1CA2CA5ACA9CA5B | |
| SCHEMBL23157787 | 0.78 | IDO1 (0.53) | IDO1AGXTCYP3A4 | |
| SCHEMBL26048600 | 0.77 | PTGS2 (0.41) | CA1CA2CA5ACA9CA5B | |
| SCHEMBL20553240 | 0.77 | CA1 (0.48) | CA1CA2CA5ACA9CA5B | |
| SCHEMBL15083519 | 0.77 | CA1 (0.42) | CA1CA2CA5ACA9CA5B | |
| SCHEMBL30874461 | 0.76 | CYP51A1 (0.49) | CA1CA2CA5ACA9CA5B | |
| SCHEMBL15590856 | 0.76 | CYP51A1 (0.49) | CYP3A4CA1CA2CA5ACA9 | |
| SCHEMBL16288084 | 0.76 | CA1 (0.41) | CYP3A4CA1CA2CA5ACA9 | |
| SCHEMBL16288086 | 0.76 | CA1 (0.41) | CA1CA2CA5ACA9CA5B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210094975-A1 | RAPAMYCIN ANALOGS AS MTOR INHIBITORS | Revolution Medicines, Inc. | 2021-04-01 | — | — | US | disclosed |
| CN-110770243-A | Rapamycin analogs as MTOR inhibitors | 锐新医药公司 | 2020-02-07 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210094975-A1 | RAPAMYCIN ANALOGS AS MTOR INHIBITORS | MTOR, RICTOR, RPTOR | IDO1 4048/4885AGXT 3057/4885CYP3A4 4795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.